

Anti-HER3-DXD(Dar8)[Patritumab deruxtecan]

Product Information

Product Name	Anti-HER3-DXD(Dar8)[Patritumab deruxtecan]
Storage temp.	Store at +4°C short term. Store at -80°C for 36 months, avoiding freeze/thaw cycles.
Catalog# / Size	GM-87820AB-100 / 100 µg GM-87820AB-1mg / 1 mg

Antibody Information


Expression System	CHO
Purity	> 95% as determined by SDS-PAGE
Aggregation	< 5% as determined by SEC-HPLC
Drug-to-Antibody Ratio (DAR)	8.0
Endotoxin	<1EU/mg
Sterility	0.22 µm Filtered
Target	HER3
Clone	Patritumab deruxtecan
Alternative Names	ERBB3
Source/Isotype	Monoclonal Human IgG1(KDEL), kappa
Application	Positive control of Cytotoxicity Assay
Description	Patritumab deruxtecan is an innovative antibody-drug conjugate (ADC) that specifically targets HER3 (human epidermal growth factor receptor 3, ErbB3). Patritumab deruxtecan employs a monoclonal antibody against HER3 to deliver the cytotoxic drug deruxtecan, a topoisomerase I inhibitor, directly to tumor cells. The antibody component specifically binds to HER3, and the drug is released inside the tumor cells, inducing DNA damage and cell death, thereby enhancing the antitumor effect. Additionally, due to the targeted delivery characteristic of ADCs, damage to normal cells is reduced, improving the safety profile of the treatment.
Formulation	10 mM NaAc-HAc, pH5.0

SDS-PAGE




After SDS-PAGE under reducing conditions, the purity of the protein is greater than 95%.

SEC-HPLC



The purity of this product is greater than 95% verified by SEC-HPLC.

RP-HPLC



The drug-to-antibody ratio (DAR) of this product is 7.73.